Related Experiment Video
Updated: Jun 9, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain. jbaselga@vhio.net
Nature Reviews. Cancer
|June 19, 2009
Summary
Aberrant signaling of the epidermal growth factor receptor (EGFR) family, particularly ERBB2 (HER2) and ERBB3 (HER3), drives cancer. New therapies targeting these receptors show promise in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Aberrant signaling of the epidermal growth factor receptor (EGFR) family is implicated in cancer development.
- Targeting individual EGFR family receptors has improved cancer treatment outcomes.
- ERBB2 (HER2) and ERBB3 (HER3) are key members of the EGFR family involved in cancer progression.
Purpose of the Study:
- To re-evaluate the roles of ERBB2 (HER2) and ERBB3 (HER3) in cancer.
- To explore novel therapeutic strategies targeting ERBB2 and ERBB3 signaling pathways.
- To review preclinical and clinical data for emerging therapies against these receptors.
Main Methods:
- Review of existing literature on ERBB2 and ERBB3 signaling.
- Analysis of preclinical and clinical data for novel targeted therapies.
- Exploration of mechanisms of action for new therapeutic agents.
Main Results:
- New therapies targeting ERBB2 and ERBB3 signaling are under investigation.
- These therapies include tyrosine kinase inhibitors, antibody-chemotherapy conjugates, and heat-shock protein inhibitors.
- Antibodies interfering with ERBB2-ERBB3 dimer formation represent a novel therapeutic approach.
Conclusions:
- Targeting ERBB2 and ERBB3 signaling pathways offers a promising avenue for cancer therapy.
- Further research and clinical trials are needed to fully elucidate the efficacy of these new agents.
- Understanding ERBB2-ERBB3 dimerization is crucial for developing effective targeted treatments.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...